ACROMEGALY: CURRENT MANAGEMENT AND THE EMERGING ROLE OF ORAL PALTUSOTINE
Authors:
- Justyna CałkaJCJustyna Całka
- Monika KowalskaMKMonika Kowalska
- Katarzyna ŚcibiszKŚKatarzyna Ścibisz
- Dominika ZdobylakDZDominika Zdobylak
- Karolina OllikKOKarolina Ollik
- Kamil HarenzaKHKamil Harenza
- Anita ZięBaAZAnita ZięBa
- Michał DominMDMichał Domin
- Mateusz TaranowiczMTMateusz Taranowicz
- Olga KowalczykOKOlga Kowalczyk
Open Access
- 2 March 2026
- journal article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (1(49))
Abstract
Introduction and aim: Acromegaly is a chronic endocrine disorder caused by sustained excess secretion of growth hormone and insulin-like growth factor I, leading to significant morbidity and increased mortality if inadequately treated. Transsphenoidal surgery remains the primary therapeutic approach; however, a substantial proportion of patients fail to achieve durable biochemical remission and require long-term medical therapy. Injectable somatostatin receptor ligands are effective but are associated with treatment burden, variable biochemical responses, and impaired quality of life. The aim of this review was to summarize current management strategies for acromegaly and to evaluate the emerging role of paltusotine, a novel orally administered somatostatin receptor agonist. Materials and Methods: This narrative review was based on a structured analysis of published clinical trials, extension studies, and review articles evaluating the pharmacological properties, clinical efficacy, and safety of paltusotine in patients with acromegaly. Results: Available evidence indicates that paltusotine provides effective suppression of growth hormone secretion and reduction of insulin-like growth factor I levels with once-daily oral administration. Clinical studies demonstrate maintenance of biochemical control in patients previously treated with injectable therapies, as well as efficacy in selected untreated individuals. Paltusotine was generally well tolerated, with predominantly mild gastrointestinal adverse events and elimination of injection-related complications. Conclusions: Paltusotine represents a promising oral alternative to injectable somatostatin receptor ligands, with the potential to reduce treatment burden, improve adherence, and maintain biochemical control. Further long-term and real-world studies are needed to fully define its role in routine clinical practice.Keywords
This publication has 30 references indexed in Scilit:
- Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participantsBritish Journal of Clinical Pharmacology, 2025
- Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experienceJournal of Endocrinological Investigation, 2023
- Modern approach to resistant acromegalyEndocrine, 2023
- Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 AgonistACS Medicinal Chemistry Letters, 2022
- Innovative therapeutics in acromegalyBest Practice & Research Clinical Endocrinology & Metabolism, 2022
- Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteersPituitary, 2022
- A Pituitary Society update to acromegaly management guidelinesPituitary, 2020
- Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegalyPituitary, 2015
- Radiotherapy for nonfunctioning pituitary adenomas: from conventional to modern stereotactic radiation techniquesNeurosurgical Review, 2007
- Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control studyActa Neurochirurgica, 2005